Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 30.
doi: 10.1038/s41391-025-01005-3. Online ahead of print.

Prostate specific membrane antigen focal ablation imaging (PSMA-FAB)

Egesta Lopci  1 , Massimo Lazzeri  2 , Vittorio Fasulo  2   3 , Davide Maffei  2   3 , Pier Paolo Avolio  2   3 , Alessandro Tallari  2   3 , Stefano Moretto  2   3 , Ludovica Cella  2   3 , Marcello Rodari  4 , Federica Mrakic Sposta  5 , Paolo Casale  2 , Nicolò Maria Buffi  2   3 , Giovanni Lughezzani  2   3
Affiliations
Review

Prostate specific membrane antigen focal ablation imaging (PSMA-FAB)

Egesta Lopci et al. Prostate Cancer Prostatic Dis. .

Abstract

The Prostate Imaging after Focal Ablation (PI-FAB) score has been recently proposed for scoring the appearance on multiparametric magnetic resonance imaging (mpMRI) of prostate cancer after focal therapy. The progressive implementation of prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) into the management of prostate cancer has revolutionized the diagnostic work-up and inspired our proposal for a dedicated PSMA Focal Ablation Imaging (PSMA-FAB) scoring system. Based on pre- and post-treatment imaging, the classification is categorized into: PSMA-FAB 1 (continue monitoring); PSMA-FAB2 (assess PSA kinetics and MRI, with biopsy to be considered in case of suspicion); and PSMA-FAB 3 (recommend biopsy). Furthermore, a combined Focal-therapy Imaging Response Evaluation Score (FIRE-SCORE) embedding PI-FAB and PSMA-FAB scores is suggested to help patient's management at follow up.

PubMed Disclaimer

Conflict of interest statement

Competing interests: EL reports receiving grant support from the Italian Ministry of Health (Ministero della Salute). The remaining authors have nothing to disclose.

References

    1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part i: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148–63. - DOI - PubMed
    1. Javier-DesLoges J, Dall’Era MA, Brisbane W, Chamie K, Washington SL 3rd, et al. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. Prostate Cancer Prostatic Dis. 2024;27:579–81. - DOI - PubMed
    1. Lovegrove CE, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, et al. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU Int. 2020;125:853–60. - DOI - PubMed
    1. Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74:422–9. - DOI - PubMed - PMC
    1. Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019;124:431–40. - DOI - PubMed

LinkOut - more resources